申请人:——
公开号:US20030220331A1
公开(公告)日:2003-11-27
The present invention is concerned with the use of compounds of formula
1
the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein p represents 0, 1, 2 or 3; q represents 0, 1, 2, 3 or 4; R
1
represents hydrogen, C
1-6
alkyl, mono-or di(C
1-6
alkyl)aminoC
1-6
alkyloxy, mercapto, C
1-6
alkylthio, C
3-7
cycloalkyl, aryl or C
1-6
alkyl substituted with mono-or di(C
1-6
alkyl)-amino, C
1-6
alkyloxy, aryl or Het; R
2
represents cyano or a radical of formula —C(═X)—Y-R
5
; wherein X represents O or S; Y represents O, S, NR
6
or a direct bond; R
5
represents hydrogen; C
3-7
cycloalkyl; aryl or optionally substituted C
1-6
alkyl; and where Y is a direct bond, R
5
may also be halo or Het; R
3
and R
4
each independently represents halo, haloC
1-6
alkyl, C
1-6
alkyl, hydroxy, C
1-6
alkyloxy, C
1-6
alkylcarbonyloxy, mercapto, C
1-6
alkylthio, C
1-6
alkylsulfonyl, C
1-6
alkylsulfinyl, haloC
1-6
alkylsulfonyl, aryl, cyano, nitro, amino, mono- and di(C
1-6
alkyl)amino or (C
1-6
alkylcarbonyl)amino; aryl represents phenyl or substituted phenyl; and Het represents an optionally substituted heterocycle; in the manufacture of a medicament useful for treating eosinophil-dependent inflammatory diseases. The invention also relates to novel compounds, their preparation and compositions comprising them.
本发明涉及使用式1化合物的N-氧化物、药学上可接受的加合物盐以及其立体化学异构体形式,其中p表示0、1、2或3;q表示0、1、2、3或4;R1表示氢、C1-6烷基、单或二(C1-6烷基)氨基C1-6烷氧基、巯基、C1-6烷基硫基、C3-7环烷基、芳基或C1-6烷基,其被单或二(C1-6烷基)-氨基、C1-6烷氧基、芳基或Het取代;R2表示氰基或式—C(═X)—Y-R5的基团;其中,X表示O或S;Y表示O、S、NR6或直接键;R5表示氢、C3-7环烷基、芳基或可选取代的C1-6烷基;当Y为直接键时,R5也可以是卤素或Het;R3和R4各自独立地表示卤素、卤素C1-6烷基、C1-6烷基、羟基、C1-6烷氧基、C1-6烷基羰氧基、巯基、C1-6烷基硫基、C1-6烷基磺酰基、C1-6烷基亚磺酰基、卤素C1-6烷基磺酰基、芳基、氰基、硝基、氨基、单和二(C1-6烷基)氨基或(C1-6烷基羰基)氨基;芳基表示苯基或取代苯基;Het表示可选取代的杂环;用于制备用于治疗嗜酸性粒细胞依赖性炎症疾病的药物。本发明还涉及新的化合物、其制备和包含它们的组合物。